{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:02Z","timestamp":1790727362498,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2017 n. 20299"],"award-info":[{"award-number":["IG2017 n. 20299"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","award":["Brian D. Novis Senior Research Grant"],"award-info":[{"award-number":["Brian D. Novis Senior Research Grant"]}],"id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PE-2016-02361261"],"award-info":[{"award-number":["PE-2016-02361261"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The oncolytic viruses have shown promising results for the treatment of multiple myeloma. However, the use of human viruses is limited by the patients\u2019 antiviral immune response. In this study, we investigated an alternative oncolytic strategy using non-human pathogen viruses as the bovine viral diarrhea virus (BVDV) that were able to interact with CD46.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We treated several human myeloma cell lines and non-myeloma cell lines with BVDV to evaluate the expression of CD46 and to study the effect on cell viability by flow cytometry. The possible synergistic effect of bortezomib in combination with BVDV was also tested. Moreover, we infected the bone marrow mononuclear cells obtained from myeloma patients and we checked the BVDV effect on different cell populations, defined by CD138, CD14, CD3, CD19, and CD56 expression evaluated by flow cytometry. Finally, the in vivo BVDV effect was tested in NOD-SCID mice injected subcutaneously with myeloma cell lines.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Human myeloma cells were selectively sensitive to BVDV treatment with an increase of cell death and, consequently, of apoptotic markers. Consistently, bone marrow mononuclear cells isolated from myeloma patients treated with BVDV, showed a significant selective decrease of the percentage of viable CD138<jats:sup>+<\/jats:sup> cells. Interestingly, bortezomib pre-treatment significantly increased the cytotoxic effect of BVDV in myeloma cell lines with a synergistic effect. Finally, the in vitro data were confirmed in an in vivo myeloma mouse model showing that BVDV treatment significantly reduced the tumoral burden compared to the vehicle.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Overall, our data indicate, for the first time, a direct oncolytic effect of the BVDV in human myeloma cells suggesting its possible use as novel alternative anti-myeloma virotherapy strategy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13045-020-00919-w","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T04:52:57Z","timestamp":1594443177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy"],"prefix":"10.1186","volume":"13","author":[{"given":"Valentina","family":"Marchica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Vescovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Vicario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Toscani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Zorzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Airoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Dalla Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Campanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Martella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Donofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-3774","authenticated-orcid":false,"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"issue":"Suppl 1","key":"919_CR1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0268-960X(10)70003-5","volume":"24","author":"A Mahindra","year":"2010","unstructured":"Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24(Suppl 1):S5\u201311.","journal-title":"Blood Rev"},{"key":"919_CR2","doi-asserted-by":"crossref","unstructured":"Kocoglu M, Badros A. The Role of Immunotherapy in Multiple Myeloma. Pharmaceuticals. 2016;9(1).","DOI":"10.3390\/ph9010003"},{"issue":"3","key":"919_CR3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/fon.10.2","volume":"6","author":"A Mahindra","year":"2010","unstructured":"Mahindra A, Cirstea D, Raje N. Novel therapeutic targets for multiple myeloma. Future Oncol. 2010;6(3):407\u201318.","journal-title":"Future Oncol"},{"issue":"8","key":"919_CR4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jvir.2013.05.040","volume":"24","author":"DY Sze","year":"2013","unstructured":"Sze DY, Reid TR, Rose SC. Oncolytic virotherapy. J Vasc Intervention Radiol. 2013;24(8):1115\u201322.","journal-title":"J Vasc Intervention Radiol"},{"issue":"16","key":"919_CR5","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/0008-5472.CAN-12-1597","volume":"73","author":"S Eisenstein","year":"2013","unstructured":"Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Chen HM, Meseck M, et al. Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res. 2013;73(16):5003\u201315.","journal-title":"Cancer Res"},{"issue":"24","key":"919_CR6","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1158\/1078-0432.CCR-14-2009","volume":"21","author":"JJ Rojas","year":"2015","unstructured":"Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic Virotherapy. Clinical Cancer. 2015;21(24):5543\u201351.","journal-title":"Clinical Cancer"},{"key":"919_CR7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fonc.2017.00114","volume":"7","author":"DE Meyers","year":"2017","unstructured":"Meyers DE, Wang AA, Thirukkumaran CM, Morris DG. Current immunotherapeutic strategies to enhance oncolytic Virotherapy. Front Oncol. 2017;7:114.","journal-title":"Front Oncol"},{"issue":"9","key":"919_CR8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"919_CR9","doi-asserted-by":"crossref","first-page":"632948","DOI":"10.1155\/2011\/632948","volume":"2011","author":"CM Thirukkumaran","year":"2011","unstructured":"Thirukkumaran CM, Morris DG. Oncolytic virotherapy for multiple myeloma: past, present, and future. Bone marrow research. 2011;2011:632948.","journal-title":"Bone marrow research"},{"issue":"12","key":"919_CR10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/cgt.2009.40","volume":"16","author":"D Dingli","year":"2009","unstructured":"Dingli D, Offord C, Myers R, Peng KW, Carr TW, Josic K, et al. Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther. 2009;16(12):873\u201382.","journal-title":"Cancer Gene Ther"},{"issue":"18","key":"919_CR11","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","volume":"18","author":"CM Thirukkumaran","year":"2012","unstructured":"Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clinical Cancer Res. 2012;18(18):4962\u201372.","journal-title":"Clinical Cancer Res"},{"issue":"3","key":"919_CR12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4161\/auto.22867","volume":"9","author":"CM Thirukkumaran","year":"2013","unstructured":"Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus modulates autophagy during oncolysis of multiple myeloma. Autophagy. 2013;9(3):413\u20134.","journal-title":"Autophagy."},{"issue":"1","key":"919_CR13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/bmt.2013.130","volume":"49","author":"CM Thirukkumaran","year":"2014","unstructured":"Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Bahlis N, Neri P, et al. Reovirus as a successful ex vivo purging modality for multiple myeloma. Bone Marrow Transplant. 2014;49(1):80\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"919_CR14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","volume":"89","author":"SJ Russell","year":"2014","unstructured":"Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89(7):926\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"919_CR15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","volume":"34","author":"HT Ong","year":"2006","unstructured":"Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol. 2006;34(6):713\u201320.","journal-title":"Exp Hematol"},{"issue":"4","key":"919_CR16","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1128\/JVI.78.4.1792-1799.2004","volume":"78","author":"K Maurer","year":"2004","unstructured":"Maurer K, Krey T, Moennig V, Thiel HJ, Rumenapf T. CD46 is a cellular receptor for bovine viral diarrhea virus. J Virol. 2004;78(4):1792\u20139.","journal-title":"J Virol"},{"issue":"3-4","key":"919_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0378-1135(93)90028-6","volume":"37","author":"SR Bolin","year":"1993","unstructured":"Bolin SR. Immunogens of bovine viral diarrhea virus. Vet Microbiol. 1993;37(3-4):263\u201371.","journal-title":"Vet Microbiol"},{"issue":"1-2","key":"919_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.prevetmed.2005.07.018","volume":"72","author":"A Lindberg","year":"2005","unstructured":"Lindberg A, Houe H. Characteristics in the epidemiology of bovine viral diarrhea virus (BVDV) of relevance to control. Prev Vet Med. 2005;72(1-2):55\u201373 discussion 215-9.","journal-title":"Prev Vet Med"},{"issue":"2","key":"919_CR19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0168-1702(00)00176-3","volume":"69","author":"VB Vassilev","year":"2000","unstructured":"Vassilev VB, Donis RO. Bovine viral diarrhea virus induced apoptosis correlates with increased intracellular viral RNA accumulation. Virus Res. 2000;69(2):95\u2013107.","journal-title":"Virus Res"},{"issue":"Pt 8","key":"919_CR20","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/0022-1317-77-8-1677","volume":"77","author":"G Zhang","year":"1996","unstructured":"Zhang G, Aldridge S, Clarke MC, McCauley JW. Cell death induced by cytopathic bovine viral diarrhoea virus is mediated by apoptosis. J Gen Virol. 1996;77(Pt 8):1677\u201381.","journal-title":"J Gen Virol"},{"issue":"1-2","key":"919_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0166-0934(01)00419-0","volume":"101","author":"G Donofrio","year":"2002","unstructured":"Donofrio G, Cavirani S, Simone T, van Santen VL. Potential of bovine herpesvirus 4 as a gene delivery vector. J Virol Methods. 2002;101(1-2):49\u201361.","journal-title":"J Virol Methods"},{"issue":"11","key":"919_CR22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1128\/CVI.00224-09","volume":"16","author":"G Donofrio","year":"2009","unstructured":"Donofrio G, Franceschi V, Capocefalo A, Taddei S, Sartori C, Bonomini S, et al. Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development. Clin Vaccine Immunol. 2009;16(11):1675\u201386.","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"919_CR23","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"6","key":"919_CR24","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1128\/JCM.37.6.2020-2023.1999","volume":"37","author":"SA Gilbert","year":"1999","unstructured":"Gilbert SA, Burton KM, Prins SE, Deregt D. Typing of bovine viral diarrhea viruses directly from blood of persistently infected cattle by multiplex PCR. J Clin Microbiol. 1999;37(6):2020\u20133.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"919_CR25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2567.2006.02467.x","volume":"119","author":"SE Christmas","year":"2006","unstructured":"Christmas SE, de la Mata Espinosa CT, Halliday D, Buxton CA, Cummerson JA, Johnson PM. Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes. Immunology. 2006;119(4):522\u20138.","journal-title":"Immunology."},{"issue":"12","key":"919_CR26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.exphem.2013.09.005","volume":"41","author":"DN Yarde","year":"2013","unstructured":"Yarde DN, Nace RA, Russell SJ. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Exp Hematol. 2013;41(12):1038\u201349.","journal-title":"Exp Hematol"},{"issue":"25","key":"919_CR27","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1038\/onc.2011.478","volume":"31","author":"KR Kelly","year":"2012","unstructured":"Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2012;31(25):3023\u201338.","journal-title":"Oncogene."},{"issue":"14","key":"919_CR28","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1158\/1078-0432.CCR-14-0553","volume":"20","author":"JY Yoo","year":"2014","unstructured":"Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, et al. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clinical Cancer Res. 2014;20(14):3787\u201398.","journal-title":"Clinical Cancer Res"},{"issue":"11","key":"919_CR29","first-page":"1375","volume":"17","author":"S Oliva","year":"2017","unstructured":"Oliva S, Gambella M, Boccadoro M, Bringhen S. Systemic virotherapy for multiple myeloma. Expert Opin Biol Ther. 2017;17(11):1375\u201387.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"919_CR30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ymthe.2017.03.026","volume":"25","author":"SJ Russell","year":"2017","unstructured":"Russell SJ, Peng KW. Oncolytic Virotherapy: a contest between apples and oranges. Mol Ther. 2017;25(5):1107\u201316.","journal-title":"Mol Ther"},{"issue":"Pt 3","key":"919_CR31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1099\/vir.0.007302-0","volume":"90","author":"HD Hummel","year":"2009","unstructured":"Hummel HD, Kuntz G, Russell SJ, Nakamura T, Greiner A, Einsele H, et al. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. J Gen Virol. 2009;90(Pt 3):693\u2013701.","journal-title":"J Gen Virol."},{"issue":"4","key":"919_CR32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clml.2015.12.005","volume":"16","author":"MY Bartee","year":"2016","unstructured":"Bartee MY, Dunlap KM, Bartee E. Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells. Clin Lymphoma Myeloma Leuk. 2016;16(4):203\u201312.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"919_CR33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5045\/kjh.2011.46.4.229","volume":"46","author":"S Raus","year":"2011","unstructured":"Raus S, Coin S, Monsurro V. Adenovirus as a new agent for multiple myeloma therapies: opportunities and restrictions. Korean J Hematol. 2011;46(4):229\u201338.","journal-title":"Korean J Hematol"},{"issue":"12","key":"919_CR34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","volume":"31","author":"A Dispenzieri","year":"2017","unstructured":"Dispenzieri A, Tong C, LaPlant B, Lacy MQ, Laumann K, Dingli D, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia. 2017;31(12):2791\u20138.","journal-title":"Leukemia."},{"key":"919_CR35","doi-asserted-by":"crossref","unstructured":"Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, et al. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clin Proc. 2019 94: 1834.","DOI":"10.1016\/j.mayocp.2019.05.006"},{"issue":"8","key":"919_CR36","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1128\/JVI.80.8.3912-3922.2006","volume":"80","author":"T Krey","year":"2006","unstructured":"Krey T, Himmelreich A, Heimann M, Menge C, Thiel HJ, Maurer K, et al. Function of bovine CD46 as a cellular receptor for bovine viral diarrhea virus is determined by complement control protein 1. J Virol. 2006;80(8):3912\u201322.","journal-title":"J Virol"},{"issue":"11","key":"919_CR37","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1357-2725(99)00092-8","volume":"31","author":"T Seya","year":"1999","unstructured":"Seya T, Hirano A, Matsumoto M, Nomura M, Ueda S. Human membrane cofactor protein (MCP, CD46): multiple isoforms and functions. Int J Biochem Cell Biol. 1999;31(11):1255\u201360.","journal-title":"Int J Biochem Cell Biol"},{"issue":"9","key":"919_CR38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.it.2004.07.004","volume":"25","author":"RC Riley-Vargas","year":"2004","unstructured":"Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, Atkinson JP. CD46: expanding beyond complement regulation. Trends Immunol. 2004;25(9):496\u2013503.","journal-title":"Trends Immunol"},{"issue":"1","key":"919_CR39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4049\/jimmunol.1900527","volume":"203","author":"MK Liszewski","year":"2019","unstructured":"Liszewski MK, Kemper C. Complement in motion: the evolution of CD46 from a complement regulator to an orchestrator of Normal cell physiology. J Immunol. 2019;203(1):3\u20135.","journal-title":"J Immunol"},{"issue":"12","key":"919_CR40","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1172\/JCI85856","volume":"126","author":"DW Sherbenou","year":"2016","unstructured":"Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, et al. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016;126(12):4640\u201353.","journal-title":"J Clin Invest"},{"issue":"23","key":"919_CR41","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/bloodadvances.2018025106","volume":"2","author":"A Lok","year":"2018","unstructured":"Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, et al. p53 regulates CD46 expression and measles virus infection in myeloma cells. Blood Adv. 2018;2(23):3492\u2013505.","journal-title":"Blood Adv"},{"issue":"4","key":"919_CR42","first-page":"458","volume":"44","author":"D Zhou","year":"2015","unstructured":"Zhou D, Zhao ZY. Advances in measles virus for cancer therapy. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015;44(4):458\u201364.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"issue":"10","key":"919_CR43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/v8100294","volume":"8","author":"S Aref","year":"2016","unstructured":"Aref S, Bailey K, Fielding A, et al. Viruses. 2016;8(10):294.","journal-title":"Viruses"},{"issue":"1-2","key":"919_CR44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-1702(02)00150-8","volume":"90","author":"B Grummer","year":"2002","unstructured":"Grummer B, Bendfeldt S, Wagner B, Greiser-Wilke I. Induction of the intrinsic apoptotic pathway in cells infected with cytopathic bovine virus diarrhoea virus. Virus Res. 2002;90(1-2):143\u201353.","journal-title":"Virus Res"},{"issue":"2","key":"919_CR45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1051\/vetres:2004059","volume":"36","author":"MC St-Louis","year":"2005","unstructured":"St-Louis MC, Massie B, Archambault D. The bovine viral diarrhea virus (BVDV) NS3 protein, when expressed alone in mammalian cells, induces apoptosis which correlates with caspase-8 and caspase-9 activation. Vet Res. 2005;36(2):213\u201327.","journal-title":"Vet Res"},{"key":"919_CR46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2018.00533","volume":"8","author":"A Slomp","year":"2018","unstructured":"Slomp A, Peperzak V. Role and regulation of pro-survival BCL-2 proteins in multiple myeloma. Front Oncol. 2018;8:533.","journal-title":"Front Oncol"},{"issue":"10","key":"919_CR47","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4161\/cc.3.10.1196","volume":"3","author":"S Le Gouill","year":"2004","unstructured":"Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle. 2004;3(10):1259\u201362.","journal-title":"Cell Cycle"},{"issue":"1","key":"919_CR48","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","volume":"100","author":"S Derenne","year":"2002","unstructured":"Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100(1):194\u20139.","journal-title":"Blood."},{"issue":"4","key":"919_CR49","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.1998.00623.x","volume":"100","author":"M Jourdan","year":"1998","unstructured":"Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100(4):637\u201346.","journal-title":"Br J Haematol"},{"issue":"4","key":"919_CR50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1024164700094","volume":"8","author":"D Chauhan","year":"2003","unstructured":"Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis. 2003;8(4):337\u201343.","journal-title":"Apoptosis."},{"key":"919_CR51","first-page":"97","volume":"185","author":"G Stewart","year":"2019","unstructured":"Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M, et al. Brit J Haematol. 2019;185:97.","journal-title":"Brit J Haematol"},{"issue":"5","key":"919_CR52","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/bloodadvances.2018025593","volume":"3","author":"CM Thirukkumaran","year":"2019","unstructured":"Thirukkumaran CM, Shi ZQ, Nuovo GJ, Luider J, Kopciuk KA, Dong Y, et al. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Adv. 2019;3(5):797\u2013812.","journal-title":"Blood Adv."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00919-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:41:30Z","timestamp":1625960490000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00919-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00919-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patient samples were obtained after informed consent according to the Declaration of Helsinki. This study was approved by local ethic committee institutional review board of Parma (Parma, Italy). (44614 12\/04\/2017).The experiments included animals which were approved by the Italian Ministry of Health review board (Italy). (0023797 10\/18\/2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.G. received research funding and honoraria from Amgen, Bristol Mayers Squibb, Celgene, Millenium Pharmaceutical, and Janssen Pharmaceutical.All other authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}